Why Supernus Shares Rallied 24% After-Hours On Tuesday
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline results in late-stage trials.
